<?xml version='1.0' encoding='utf-8'?>
<document id="23340958"><sentence text="Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans." /><sentence text="To date, the in vitro-in vivo correlation (IVIVC) of P-glycoprotein (P-gp)-mediated drug-drug interaction (DDI) at the blood-brain barrier (BBB) in rats indicated that the cutoff value to significantly affect the brain penetration of digoxin was [I,unbound/Ki] of 1, where I,unbound is the unbound plasma concentration of P-gp inhibitors"><entity charOffset="234-241" id="DDI-PubMed.23340958.s2.e0" text="digoxin" /></sentence><sentence text=" On the basis of the IVIVC in rats, we speculated that clinically used P-gp inhibitors do not cause DDI at the human BBB, because none of the compounds studied was [I,unbound/Ki]&gt;1 at therapeutic doses" /><sentence text=" Recently, positron emission tomography studies with P-gp substrates, such as [(11)C]verapamil, [(11)C]N-desmethyl loperamide, and [(11)C]loperamide, together with potent P-gp inhibitors, have indicated that increases in the influx rate constant for brain entry were observed in humans"><entity charOffset="78-94" id="DDI-PubMed.23340958.s4.e0" text="[(11)C]verapamil" /><entity charOffset="96-125" id="DDI-PubMed.23340958.s4.e1" text="[(11)C]N-desmethyl loperamide" /><entity charOffset="131-148" id="DDI-PubMed.23340958.s4.e2" text="[(11)C]loperamide" /><pair ddi="false" e1="DDI-PubMed.23340958.s4.e0" e2="DDI-PubMed.23340958.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23340958.s4.e0" e2="DDI-PubMed.23340958.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23340958.s4.e0" e2="DDI-PubMed.23340958.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23340958.s4.e1" e2="DDI-PubMed.23340958.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23340958.s4.e1" e2="DDI-PubMed.23340958.s4.e2" /></sentence><sentence text=" Therefore, we aimed to retrospectively analyze the results of P-gp-mediated DDIs with in vitro P-gp inhibition assays and to confirm the appropriate cutoff value" /><sentence text=" In vitro P-gp inhibition assays using verapamil, N-desmethyl loperamide, and loperamide as P-gp probe substrates were performed in human multidrug resistance protein 1-expressing LLC-PK1 cells"><entity charOffset="39-48" id="DDI-PubMed.23340958.s6.e0" text="verapamil" /><entity charOffset="50-72" id="DDI-PubMed.23340958.s6.e1" text="N-desmethyl loperamide" /><entity charOffset="78-88" id="DDI-PubMed.23340958.s6.e2" text="loperamide" /><pair ddi="false" e1="DDI-PubMed.23340958.s6.e0" e2="DDI-PubMed.23340958.s6.e0" /><pair ddi="false" e1="DDI-PubMed.23340958.s6.e0" e2="DDI-PubMed.23340958.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23340958.s6.e0" e2="DDI-PubMed.23340958.s6.e2" /><pair ddi="false" e1="DDI-PubMed.23340958.s6.e1" e2="DDI-PubMed.23340958.s6.e1" /><pair ddi="false" e1="DDI-PubMed.23340958.s6.e1" e2="DDI-PubMed.23340958.s6.e2" /></sentence><sentence text=" The efflux ratios decreased in the presence of P-gp inhibitors, and the Ki of tariquidar was 10 nmol/L, regardless of probe substrates" /><sentence text=" Taking the in vitro Ki and unbound plasma concentrations in clinical DDI studies together, the criterion [I,unbound/Ki] of 1 was an appropriate cutoff limit to observe significant P-gp-mediated DDI at the BBB in humans" /><sentence text=" On the other hand, no significant DDI was observed in cases in which [I,unbound/Ki] was less than 0" /><sentence text="1" /><sentence text=" This criterion was comparable to the previous IVIVC result in rats" /><sentence text="" /></document>